{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:36:55Z","timestamp":1775147815731,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Direct acting antiretrovirals (DAA) are effective for individuals who are infected with chronic hepatitis C virus (HCV), yet many people go without access to these lifesaving treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We conducted a non-randomized study evaluating treatment data for patients in outpatient treatment for opioid use disorder (OUD) at a private clinic. Patients who were HCV-positive, had been in OUD treatment for at least 4 weeks, and engaged in integrated HCV treatment with DAA (co-located within their treatment for OUD) were compared to patients with HCV who only received OUD treatment. We evaluated HCV cure; OUD medication adherence, treatment utilization and retention; and illicit substance use for those engaged in treatment between 9\/2016 and 1\/2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy-four patients completed integrated HCV-OUD treatment with DAA, with 87.8% achieving cure. Of the 66 who completed treatment and were subsequently evaluated for sustained viral response 98.5% were cured. Patients who received integrated HCV and OUD treatment in our clinic, stayed in OUD treatment longer, demonstrated higher OUD medication adherence, and used less opioids or cocaine compared to HCV-infected patients (<jats:italic>n<\/jats:italic> = 572) being treated only for OUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We have reported on a reproducible intervention that lends itself to outpatient OUD treatment. Analyses demonstrate the potential positive impact HCV treatment has on OUD recovery, including reduction in opioid and cocaine use and increased retention in care<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Co-locating HCV treatment with existing OUD treatment is feasible, effective, and demonstrates positive outcomes for the treatment of both conditions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.932306","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T04:42:37Z","timestamp":1663130557000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic"],"prefix":"10.3389","volume":"13","author":[{"given":"Phyllis","family":"Losikoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordon D.","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Dig Liver Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users - a hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health."},{"key":"B4","volume-title":"Viral Hepatitis Surveillance Report, United States, 2019","year":"2021"},{"key":"B5","unstructured":"2016"},{"key":"B6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jmv.23777","article-title":"Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C","volume":"86","author":"Arase","year":"2014","journal-title":"J Med Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/hep.26229","article-title":"Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C","volume":"58","author":"Kraus","year":"2013","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","author":"Smith-Palmer","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1038\/ajg.2009.346","article-title":"Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C","volume":"104","author":"John-Baptiste","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsat.2016.01.009","article-title":"Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders","volume":"66","author":"Carey","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.drugpo.2017.12.014","article-title":"Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era","volume":"52","author":"Valerio","year":"2018","journal-title":"Int J Drug Policy."},{"key":"B13","unstructured":"2021"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"Zeremski","year":"2013","journal-title":"World J Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.20132","article-title":"Hepatitis C virus-infected patients report communication problems with physicians","volume":"39","author":"Zickmund","year":"2004","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40271-018-0332-6","article-title":"A diagnosis of hepatitis C\u2014insights from a study on patients' experiences","volume":"39","author":"Treloar","year":"2010","journal-title":"Aust Fam Physician."},{"key":"B17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.idc.2018.02.001","article-title":"Treatment of chronic hepatitis C in patients receiving opioid agonist therapy","volume":"32","author":"Norton","year":"2018","journal-title":"Infect Dis Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.drugpo.2018.10.012","article-title":"Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: the C-SCOPE study","volume":"63","author":"Grebely","year":"2019","journal-title":"Int J Drug Policy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study","volume":"18","author":"Zelenev","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/ciaa142","article-title":"Modeling combination hepatitis C Virus treatment and prevention strategies in a network of people who inject drugs in the United States","volume":"72","author":"Zelenev","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S2468-1253(18)30001-3","article-title":"Time to end treatment restrictions for people with hepatitis C who inject drugs","volume":"3","author":"Rosenthal","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"ofy001","DOI":"10.1093\/ofid\/ofy001","article-title":"Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies","volume":"5","author":"Grebely","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugpo.2019.03.001","article-title":"Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada","volume":"72","author":"Selfridge","year":"2019","journal-title":"Int J Drug Policy."},{"key":"B24","volume-title":"Policy Statement: Hepatitis C Infection","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13722-018-0111-7","article-title":"Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care","volume":"13","author":"Martin","year":"2018","journal-title":"Addict Sci Clin Pract."},{"key":"B26","article-title":"SPSS v25","author":"IBM","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J Subst Abuse Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/MLR.0000000000000121","article-title":"Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States","volume":"52","author":"Bachhuber","year":"2014","journal-title":"Med Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"ofaa310","DOI":"10.1093\/ofid\/ofaa310","article-title":"Optimizing hepatitis C virus (HCV) treatment in a US colocated HCV\/opioid agonist therapy program","volume":"7","author":"Habchi","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41124-018-0036-5","article-title":"Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia","volume":"3","author":"Richmond","year":"2018","journal-title":"Hepatol Med Policy."},{"key":"B32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","article-title":"\u201cHepatitis C treatment turned me around:\u201d psychological and behavioral transformation related to hepatitis C treatment","volume":"153","author":"Batchelder","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/cit263","article-title":"Understanding barriers to hepatitis C virus care and stigmatization from a social perspective","volume":"57","author":"Treloar","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Internal Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3122\/jabfm.2019.03.180286","article-title":"Hepatitis C updated and expanding the role of primary care","volume":"32","author":"Simoncini","year":"2019","journal-title":"J Am Board Fam Med."},{"key":"B37","unstructured":"2021"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.932306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T04:42:43Z","timestamp":1663130563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.932306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":37,"alternative-id":["10.3389\/fpsyt.2022.932306"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.932306","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"article-number":"932306"}}